T90/44 (9.3 antigen). A cell surface molecule with a function in human T cell activation
- PMID: 3021470
- DOI: 10.1002/eji.1830161017
T90/44 (9.3 antigen). A cell surface molecule with a function in human T cell activation
Abstract
T90/44 is a cell surface antigen which is present on human T cells of the helper and cytotoxic subsets and which binds the 9.3 monoclonal antibody (9.3 mAb). It is expressed in the form of 90-kDa disulfide-bonded dimers of a 44-kDa polypeptide and of free 44-kDa subunits. The function of T90/44 was investigated in a series of T cell function assays. 9.3 mAb was found to inhibit the activation of class II-restricted cloned T helper cells derived from leprosy patients and reactive with M. leprae antigens. The inhibition was first found at 1-10 ng/ml 9.3 mAb and regularly increased with the antibody concentration. The extent of the inhibition varied among different T cell clones in proportion to the respective different levels of T90/44 expression at their cell surface. The proliferative responses of peripheral blood lymphocytes (PBL) to purified protein derivative of M. tuberculosis (PPD) and tetanus toxoid were enhanced by the 9.3 mAb resulting in up to 20-30-fold increase of [3H]-thymidine incorporation. After phytohemagglutinin-induced activation of PBL, the number of T90/44 molecules per cell expressed at the cell surface rose from day 0 to day 7 by a factor of about 10. High concentrations of 9.3 mAb (5-10 micrograms/ml) at low cell densities and in the presence of monocytes in culture media supplemented by fetal calf serum were directly mitogenic for resting lymphocytes. The cytolytic effector functions of class I-restricted cytotoxic T lymphocytes (CTL) were not modulated by 9.3 mAb. The mixed lymphocyte reactions of three class I-restricted CTL to their specific target cells were found not to be significantly influenced by 9.3 mAb. In conclusion it is proposed that an antigen-independent T cell activation pathway can be entered at T90/44.
Similar articles
-
Evidence for a regulatory role of the T8 (CD8) antigen in antigen-specific and anti-T3-(CD3)-induced lytic activity of allospecific cytotoxic T lymphocyte clones.Eur J Immunol. 1986 Nov;16(11):1363-71. doi: 10.1002/eji.1830161109. Eur J Immunol. 1986. PMID: 2430810
-
Antibodies to the L3T4 and Lyt-2 molecules interfere with antigen receptor-driven activation of cloned murine T cells.J Immunol. 1987 Aug 1;139(3):657-64. J Immunol. 1987. PMID: 2955046
-
Helper effector function of human T cells stimulated by anti-CD3 mAb can be enhanced by co-stimulatory signals and is partially dependent on CD40-CD40 ligand interaction.Eur J Immunol. 1994 Mar;24(3):508-17. doi: 10.1002/eji.1830240303. Eur J Immunol. 1994. PMID: 7510232
-
[Analysis of immune mechanisms using monoclonal antibodies].Nihon Rinsho. 1983;41(4):741-9. Nihon Rinsho. 1983. PMID: 6310179 Review. Japanese. No abstract available.
-
A monoclonal antibody that blocks class II histocompatibility-related immune interactions.Hum Immunol. 1984 May;10(1):23-40. doi: 10.1016/0198-8859(84)90083-1. Hum Immunol. 1984. PMID: 6233239 Review.
Cited by
-
Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation.J Exp Med. 1991 Mar 1;173(3):721-30. doi: 10.1084/jem.173.3.721. J Exp Med. 1991. PMID: 1847722 Free PMC article.
-
T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1.Proc Natl Acad Sci U S A. 1990 Jul;87(13):5031-5. doi: 10.1073/pnas.87.13.5031. Proc Natl Acad Sci U S A. 1990. PMID: 2164219 Free PMC article.
-
Signaling by lymphocyte function-associated antigen 1 (LFA-1) in B cells: enhanced antigen presentation after stimulation through LFA-1.J Exp Med. 1992 Jan 1;175(1):1-7. doi: 10.1084/jem.175.1.1. J Exp Med. 1992. PMID: 1346153 Free PMC article.
-
A novel T-lymphocyte molecule that may function in the induction of self-tolerance and MHC-restriction within the human thymic microenvironment.Immunology. 1988 May;64(1):101-5. Immunology. 1988. PMID: 2968304 Free PMC article.
-
Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma.Cancer Gene Ther. 2012 Dec;19(12):811-7. doi: 10.1038/cgt.2012.69. Epub 2012 Oct 5. Cancer Gene Ther. 2012. PMID: 23037806 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources